Esophageal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: June 30, 2022 Report Code: GDGMDHC22224IDB-ST

Select Item

Esophageal cancer symptoms include cough, difficulty swallowing, chest pain, pressure or burning, and weight loss. Predisposing factors include age, smoking, obesity, and bile reflux. Treatment includes chemotherapy, radiation therapy, and surgery.

The Esophageal Cancer pipeline drugs market research report provides an overview of the Esophageal Cancer (Oncology) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer (Oncology) and features dormant and discontinued projects.

Esophageal Cancer Pipeline Drugs Market by Key Targets

Some of the key targets of the Esophageal Cancer pipeline drugs market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Epidermal Growth Factor Receptor, Tubulin, Cells Expressing Epidermal Growth Factor Receptor, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Cytotoxic T Lymphocyte Protein 4, Receptor Tyrosine Protein Kinase ERBB 2, Tumor Necrosis Factor Receptor Superfamily Member 9, and Tyrosine Protein Phosphatase Non Receptor Type 11.

Esophageal Cancer Pipeline Drugs Market, by Targets

Esophageal Cancer Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key Mechanism of Actions in the Esophageal Cancer Pipeline Drugs Market

Some of the key mechanism of actions of the Esophageal Cancer pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Tubulin Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Receptor Tyrosine Protein Kinase ERBB 2 Inhibitor, Tyrosine Protein Phosphatase Non Receptor Type 11 Inhibitor, Epidermal Growth Factor Receptor Antagonist, Epidermal Growth Factor Receptor Inhibitor, and Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist.

Esophageal Cancer Pipeline Drugs Market, by Mechanism of Actions

Esophageal Cancer Pipeline Drugs Market, by Mechanism of Actions

For more mechanism of action insights, download a free report sample

Key Routes of Administration in the Esophageal Cancer Pipeline Drugs Market

The routes of administration in the Esophageal Cancer pipeline drugs market are intravenous, oral, parenteral, subcutaneous, intravenous drip, intratumor, intravesical, intraperitoneal, intramuscular, and intradermal.

Esophageal Cancer Pipeline Drugs Market, by Routes of Administration

Esophageal Cancer Pipeline Drugs Market, by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Esophageal Cancer Pipeline Drugs Market

The molecule types in the Esophageal Cancer pipeline drugs market are monoclonal antibody, small molecule, monoclonal antibody conjugated, gene-modified cell therapy, cell therapy, fusion protein, oncolytic virus, subunit vaccine, synthetic peptide, and biologic.

Esophageal Cancer Pipeline Drugs Market, by Molecule Types

Esophageal Cancer Pipeline Drugs Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Esophageal Cancer Pipeline Drugs Market

Some of the key companies in the Esophageal Cancer pipeline drugs market are F. Hoffmann-La Roche Ltd, Jiangsu Hengrui Medicine Co Ltd, BeiGene Ltd, Boehringer Ingelheim International GmbH, Akeso Inc, Bristol-Myers Squibb Co, Jacobio Pharmaceuticals Group Co Ltd, Merck & Co Inc, Innovent Biologics Inc, and Novartis AG.

Esophageal Cancer Pipeline Drugs Market, by Companies

Esophageal Cancer Pipeline Drugs Market, by Companies

To know more about the companies, download a free report sample

Esophageal Cancer Pipeline Drugs Market Report Overview

Key Targets Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Epidermal Growth Factor Receptor, Tubulin, Cells Expressing Epidermal Growth Factor Receptor, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Cytotoxic T Lymphocyte Protein 4, Receptor Tyrosine Protein Kinase ERBB 2, Tumor Necrosis Factor Receptor Superfamily Member 9, and Tyrosine Protein Phosphatase Non Receptor Type 11
Key Mechanism of Actions Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Tubulin Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Receptor Tyrosine Protein Kinase ERBB 2 Inhibitor, Tyrosine Protein Phosphatase Non Receptor Type 11 Inhibitor, Epidermal Growth Factor Receptor Antagonist, Epidermal Growth Factor Receptor Inhibitor, and Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist
Key Routes of Administration Intravenous, Oral, Parenteral, Subcutaneous, Intravenous Drip, Intratumor, Intravesical, Intraperitoneal, Intramuscular, and Intradermal
Key Molecule Types Monoclonal Antibody, Small Molecule, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Cell Therapy, Fusion Protein, Oncolytic Virus, Subunit Vaccine, Synthetic Peptide, and Biologic
Key Companies F. Hoffmann-La Roche Ltd, Jiangsu Hengrui Medicine Co Ltd, BeiGene Ltd, Boehringer Ingelheim International GmbH, Akeso Inc, Bristol-Myers Squibb Co, Jacobio Pharmaceuticals Group Co Ltd, Merck & Co Inc, Innovent Biologics Inc, and Novartis AG

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
  • Reviews of pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • Evaluation of Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Esophageal Cancer (Oncology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AbbVie Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
Affimed GmbH
AIMM Therapeutics BV
Akeso Inc
Alkermes Plc
Alphamab Oncology
Alpine Immune Sciences Inc
Ambrx Biopharma Inc
amcure GmbH
Amgen Inc
AMI Onco Theranostics LLC
Anaveon AG
Anhui Anke Biotechnology (Group) Co Ltd
Anhui Kedgene Biotechnology Co Ltd
Apexigen Inc
Apollomics Inc
Aptacure Therapeutics Ltd
Arcus Biosciences Inc
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Ascentawits Pharmaceuticals Ltd
AskGene Pharma Inc
Astellas Pharma Inc
AstraZeneca Plc
Atreca Inc
Aurigene Discovery Technologies Ltd
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene Ltd
Beijing Biostar Technologies Ltd
Beijing Immunochina Pharmaceuticals Co Ltd
Beijing Scitech-MQ Pharmaceuticals Ltd
Beijing Weiyuan Likang Biological Technology Co Ltd
Bexion Pharmaceuticals LLC
Bicycle Therapeutics Plc
Bio-Synectics Inc
BioMed Valley Discoveries Inc
BioNTech SE
Biostage Inc
BioStar Pharmaceuticals Inc
Biotheus Inc
Boehringer Ingelheim International GmbH
BrightGene Bio-Medical Technology Co Ltd
Bristol-Myers Squibb Co
CanBas Co Ltd
Cantargia AB
CARsgen Therapeutics Ltd
CDR-Life Inc
Cedilla Therapeutics
Celldex Therapeutics Inc
Centrymed Pharmaceutical Inc
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chong Kun Dang Pharmaceutical Corp
Chongqing Precision Biotech Co Ltd
Chugai Pharmaceutical Co Ltd
Coherent Biopharma
Cotinga Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Curegenix Inc
Curis Inc
Cyclacel Pharmaceuticals Inc
Cytlimic Inc
Cytocraft Bio-Tech Development Co Ltd
CytomX Therapeutics Inc
DAE HWA Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Delta-Fly Pharma Inc
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Dragonfly Therapeutics Inc
Dyadic International Inc
Eisai Co Ltd
Elevation Oncology Inc
Eli Lilly and Co
Ella Therapeutics Ltd
Elucida Oncology Inc
Ennaid Therapeutics LLC
Etern BioPharma Co Ltd
Evopoint Bioscience Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Genentech USA Inc
GenFleet Therapeutics (Shanghai) Inc
Genmab AS
GenoImmune Therapeutics Biotechnology Co Ltd
Gilead Sciences Inc
GLG Pharma SA
GlycoNex Inc
Glycotope GmbH
GlyTherix Ltd
GO Therapeutics Inc
GSK plc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou Anjie Biomedical Technology Co Ltd
Guangzhou Saliai Stemcell Science and Technology Co Ltd
Guangzhou Yinming Biomedical Technology Co Ltd
Hangzhou Bensheng Pharmaceutical Co Ltd
Hangzhou Neoantigen Therapeutics Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
HEC Pharma Co Ltd
Huabo Biopharm (Shanghai) Co Ltd
Huahui Anjian (Beijing) Biotechnology Co Ltd
Hualan Biological Engineering Inc
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
I-Mab
Ideaya Biosciences Inc
Idera Pharmaceuticals Inc
Immatics NV
Immix BioPharma Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneSensor Therapeutics Inc
Immunocore Limited
Immvira Co Ltd
Incyte Corp
Inhibrx Inc
Innate Pharma SA
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Ipsen SA
Istari Oncology Inc
Jacobio Pharmaceuticals Group Co Ltd
JenKem Technology Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangxi Qingfeng Pharmaceutical Co Ltd
Johnson & Johnson
Keythera Pharmaceuticals Co Ltd
Kintor Pharmaceutical Ltd
Kymab Ltd
Laekna Therapeutics Shanghai Co Ltd
LaNova Medicines Ltd
Leap Therapeutics Inc
Lepu Biopharma Co Ltd
LEXEO Therapeutics LLC
LIfT BioSciences Ltd
Liminatus Pharma LLC
LipoMedix Pharmaceutical Inc
Lumosa Therapeutics Co Ltd
Luye Pharma Group Ltd
Lycera Corp
Lyvgen Biopharma Ltd
MaxiVAX SA
MedGene Therapeutics Inc
Medical Guidance Systems LLC
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Merus NV
Modra Pharmaceuticals BV
Molecular Templates Inc
Myeloid Therapeutics Inc
Nanjing Sanhome Pharmaceutical Co Ltd
New Beta Innovation Ltd
NextCure Inc
NGM Biopharmaceuticals Inc
NovaRock Biotherapeutics Inc
Novartis AG
Novita Pharmaceuticals Inc
OBI Pharma Inc
Omeros Corp
Oncolys BioPharma Inc
Onconova Therapeutics Inc
Ono Pharmaceutical Co Ltd
PDS Biotechnology Corp
Pfizer Inc
Pharma Mar SA
PharmaDrug Inc
Pieris Pharmaceuticals Inc
PlantForm Corp
POINT Biopharma Global Inc
Precigen Inc
Prelude Therapeutics Inc
Privo Technologies Inc
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
Purple Biotech Ltd
Qilu Pharmaceutical Co Ltd
Quadriga BioSciences Inc
Rafael Pharmaceuticals Inc
Rakuten Medical Inc
Rapa Therapeutics LLC
RAPT Therapeutics Inc
RaQualia Pharma Inc
RemeGen Co Ltd
Repare Therapeutics Inc
Replimune Ltd
Rhizen Pharmaceuticals SA
Rizen (Suzhou) Biosciences Co Ltd
RNR BioMedical Inc
Samyang Biopharmaceuticals Corp
Sanofi
Sapience Therapeutics Inc
Scancell Holdings Plc
Seagen Inc
Seven and Eight Biopharmaceuticals Corp
Shanghai Escugen Biotechnology Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Institute of Biological Products Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Miracogen Inc
Shanghai Xunhe Pharmaceutical Technology Co Ltd
Shanghai Yihao Biotechnology Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shenyang Dongxing Pharmaceutical Co Ltd
Shenzhen BinDeBio Ltd
Shenzhen NeoCura Biotechnology Corp
Shenzhen Salubris Pharmaceuticals Co Ltd
Shijiazhuang Sagacity New Drug Development Co Ltd
Shionogi & Co Ltd
Simcere Pharmaceutical Group Ltd
Simcha Therapeutics Inc
Sino Biopharmaceutical Ltd
SinoCelltech Group Ltd
Smerud Medical Research International AS
Soricimed Biopharma Inc
Sorrento Therapeutics Inc
Starpharma Holdings Ltd
Steba Biotech SA
Stemirna Therapeutics Ltd
Stemsynergy Therapeutics Inc
Supratek Pharma Inc
Sutro Biopharma Inc
Suzhou Hitebio Biotechnology Co Ltd
Suzhou Medilink Therapeutics Ltd
Suzhou Stainwei Biotech Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
Symphogen A/S
Systimmune Inc
T-Cure Bioscience Inc
Tachyon Therapeutics Inc
TAE Life Sciences LLC
Taiho Oncology Inc
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
Telix Pharmaceuticals Ltd
Tessa Therapeutics Ltd
TOT Biopharm Co Ltd
Transcenta Holding Ltd
Transgene Biotek Ltd
Transgene SA
Turnstone Biologics Inc
Tyg Oncology Ltd
UCB SA
United Immunity Co Ltd
VM Discovery Inc
Waterstone Hanxbio Pty Ltd
Wuhan Binhui Biotechnology Co Ltd
Xiangxue Life Sciences
XuanZhu Biological Technology Co Ltd
Zai Lab Ltd
Zhuhai Beihai Biotech Co Ltd
Zymeworks Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Esophageal Cancer – Overview

Esophageal Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Esophageal Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Esophageal Cancer – Companies Involved in Therapeutics Development

Esophageal Cancer – Drug Profiles

Esophageal Cancer – Dormant Projects

Esophageal Cancer – Discontinued Products

Esophageal Cancer – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

  • What are the key targets of the Esophageal Cancer pipeline drugs market?

    Some of the key targets of the Esophageal Cancer pipeline drugs market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Epidermal Growth Factor Receptor, Tubulin, Cells Expressing Epidermal Growth Factor Receptor, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Cytotoxic T Lymphocyte Protein 4, Receptor Tyrosine Protein Kinase ERBB 2, Tumor Necrosis Factor Receptor Superfamily Member 9, and Tyrosine Protein Phosphatase Non Receptor Type 11.

  • What are the key mechanism of actions of the Esophageal Cancer pipeline drugs market?

    Some of the key mechanism of actions of the Esophageal Cancer pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Tubulin Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Receptor Tyrosine Protein Kinase ERBB 2 Inhibitor, Tyrosine Protein Phosphatase Non Receptor Type 11 Inhibitor, Epidermal Growth Factor Receptor Antagonist, Epidermal Growth Factor Receptor Inhibitor, and Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist.

  • What are the key routes of administration in the Esophageal Cancer pipeline drugs market?

    The routes of administration in the Esophageal Cancer pipeline drugs market are intravenous, oral, parenteral, subcutaneous, intravenous drip, intratumor, intravesical, intraperitoneal, intramuscular, and intradermal.

  • What are the key molecule types in the Esophageal Cancer pipeline drugs market?

    The molecule types in the Esophageal Cancer pipeline drugs market are monoclonal antibody, small molecule, monoclonal antibody conjugated, gene-modified cell therapy, cell therapy, fusion protein, oncolytic virus, subunit vaccine, synthetic peptide, and biologic.

  • Which are the key companies in the Esophageal Cancer pipeline drugs market?

    Some of the key companies in the Esophageal Cancer pipeline drugs market F. Hoffmann-La Roche Ltd, Jiangsu Hengrui Medicine Co Ltd, BeiGene Ltd, Boehringer Ingelheim International GmbH, Akeso Inc, Bristol-Myers Squibb Co, Jacobio Pharmaceuticals Group Co Ltd, Merck & Co Inc, Innovent Biologics Inc, and Novartis AG.

Esophageal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Esophageal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Esophageal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more